Insider News of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) lost -6.35 Percent and closed its previous trading session at $3.54. The stock traded with the average Volume of 1.24 Million at the end of last session.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) has the Market Capitalization of 449.05 Million. The Stock has its 52-week High of $8.07 and 52-Week Low of $3.30 and it touched its 52-week high on 10/10/17 and 52-Week Low on 06/28/18


The company reported its last earnings Actual EPS of $-0.18/share. While, the analyst predicted that the company could provide an EPS of $-0.15/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.03/share which shows an Earnings Surprise of -20 Percent.

Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -15.91% where SMA50 and SMA200 are -21.57% and -25.36% respectively.

The company shows its Return on Assets (ROA) value of -98.8%. While it’s Return on Investment (ROI) value is -190.1%.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) currently has a Weekly Volatility of 8.02% percent while its Monthly Volatility is at 5.70% percent. While talking about Performance of the Stock, Keryx Biopharmaceuticals Inc. currently has a Weekly performance of -14.9%, monthly performance percentage is -15.51 percent, Quarterly performance is -32.57 percent, 6 months performance shows a percent value of -17.29% and Yearly Performance is -45.54 percent.

Company Profile:

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.